Low-Dose Colchicine in Patients With Type 2 Diabetes and Recent Myocardial Infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT).

François RoubilleNadia BouabdallaouiSimon KouzDavid D WatersRafael DiazAldo P MaggioniFausto J PintoJean C GrégoireHabib GamraGhassan S KiwanColin BerryJosé López-SendónWolfgang KoenigLaurent DelormeMeyer ElbazPierre CosteMylène ProvencherZohar BassevitchLucie BlondeauPhilippe L L'AllierMarie-Claude GuertinJean Claude Tardif

Published in: Diabetes care (2024)

Among patients with T2D and a recent myocardial infarction, colchicine, 0.5 mg daily, leads to a large reduction of cardiovascular events. These results support the conduct of the COLCOT-T2D trial in primary prevention.

Keyphrases

cardiovascular events
low dose
phase iii
study protocol
coronary artery disease
heart failure
left ventricular
phase ii
clinical trial
cardiovascular disease
high dose
randomized controlled trial
open label
type diabetes
atrial fibrillation